Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Total Non-Current Liabilities (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 306.65% to $19.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $19.4 million, a 306.65% increase, with the full-year FY2025 number at $2.9 million, down 60.39% from a year prior.
  • Total Non-Current Liabilities was $19.4 million for Q4 2025 at PharmaCyte Biotech, up from $1.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $19.4 million in Q4 2025 to a low of $586581.0 in Q2 2023.
  • A 3-year average of $8.2 million and a median of $5.2 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 1165.17% in 2024, then crashed 90.61% in 2025.
  • PharmaCyte Biotech's Total Non-Current Liabilities stood at $5.2 million in 2023, then dropped by 8.84% to $4.8 million in 2024, then soared by 306.65% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Total Non-Current Liabilities are $19.4 million (Q4 2025), $1.5 million (Q3 2025), and $2.9 million (Q2 2025).